1. Introduction {#sec1}
===============

Aristolochic acids (AAs) are structurally related nitrophenanthrene carboxylic acid derivatives found primarily in the *Aristolochia*, *Bragantia*, and *Asarum* species[@bib1]. These acids have been used in obstetrics, and in the treatment of tumors and snake bites since antiquity. AAs exhibit multiple pharmacological effects, such as antiviral, antibacterial, and antineoplastic activities, and have been investigated as lead compounds by pharmaceutical companies in Germany for approximately 20 years until they were found to be carcinogenic in rats[@bib2]. Their other main adverse effect is nephrotoxicity, which was initially reported in a number of women who had followed a slimming regimen with medicinal herbs containing AAs in Belgium and was subsequently confirmed by extensive studies in animals and humans[@bib3], [@bib4], [@bib5], [@bib6]. Epidemiological investigations have indicated that intake of herbs containing AAs and grains contaminated by AAs has been associated with the etiology of acute and chronic kidney diseases, which has caused global public health concerns, especially in Asia[@bib7], [@bib8], [@bib9].

Great efforts have been made to investigate the pathogenesis of renal injury and dysfunction induced by AAs. The nephrotoxicity of AAs has been found to be manifested by rapidly progressive interstitial nephropathy[@bib10], [@bib11], [@bib12] and thought to occur through multiple mechanisms, such as DNA damage, apoptosis, immune inflammation, oxidative stress, and endoplasmic reticulum stress[@bib13], [@bib14], [@bib15], [@bib16], [@bib17]. However, the underlying mechanism of renal injury and dysfunction associated with AAs remains incompletely understood.

Discovering functional endogenous metabolites is very important for understanding the complex pathological process of AAs-induced nephrotoxicity. Metabolomics is a promising molecular profiling technology that provides high-throughput and unbiased evaluation of the metabolic responses of organisms to toxic stimuli, which makes it especially useful in the discovery of novel toxic biomarkers and elucidation of toxic mechanisms[@bib18]^,^[@bib19]. Various liquid chromatography--mass spectrometry (LC--MS) and gas chromatograph (GC)--MS-based metabolomics methods have been developed to study the nephrotoxicity of AAs[@bib20], [@bib21], [@bib22], [@bib23], [@bib24]. These studies provide a wealth of information on the perturbation of various metabolites in biological samples for understanding the toxic effects of AAs, but little is known about their spatial distribution within the kidney, which is vital to unveiling the complex pathological processes underlying AAs-induced nephrotoxicity.

Mass spectrometry imaging (MSI) is a novel label-free and sensitive imaging technique that is regarded as most suitable for *in situ* metabolomics because of its ability to provide molecular and spatial information simultaneously. Desorption electrospray ionization MSI (DESI-MSI) under ambient conditions, matrix-assisted laser desorption ionization MSI (MALDI-MSI), and secondary ion MS have been used for *in situ* analysis of lipids, metabolites, drugs, and metals in various biological tissue sections[@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31]. Previously, our group developed a sensitive and high-coverage air-flow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI-MSI) technology and AFADESI-MSI based *in situ* metabolomics method, and demonstrated their outstanding performance and great potential in areas of *in situ* screening of cancer biomarkers, label-free molecular pathological diagnosis, and action mechanism study of drug candidates[@bib32], [@bib33], [@bib34], [@bib35].

In the present study, an *in situ* metabolomics method was developed by combining AFADESI with an ultra-high resolution Q-OT-qIT mass spectrometer, aimed to investigate the acute nephrotoxicity effect induced by AA exposure. First, an AA-induced nephrotoxicity (AAN) rat model was produced by oral administration of aristolochic acids I (AAI) and verified by biochemical and histopathological examination. Then, various endogenous metabolites in rat kidney sections were detected by using the AFADESI-MSI method. A subsequent orthogonal partial least squares-discriminant analysis was performed to investigate the *in situ* metabolic changes in AAs' nephrotoxicity. Finally, the differentiating metabolites were tentatively identified and imaged, providing a new perspective on the nephrotoxicity mechanism of AAI in rat. The research strategy is illustrated in [Scheme 1](#sch1){ref-type="fig"}.Scheme 1The research strategy for *in situ* metabolomics in nephrotoxicity of aristolochic acids I. Scale bar: 2.5 mm.Scheme 1

2. Materials and methods {#sec2}
========================

2.1. Chemicals and reagents {#sec2.1}
---------------------------

Aristolochic acid I was obtained from the National Institute for Food and Drug Control (Beijing, China). High-performance liquid chromatography-grade acetonitrile and methanol were purchased from Merck (Muskegon, MI, USA). Ultrapure water (Wahaha, Hangzhou, China) was obtained from a local market and used throughout the experiment.

2.2. Animals {#sec2.2}
------------

Twelve Sprague--Dawley rats (8 weeks old) were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The rats were randomized to the AAN (*n* = 6) and control groups (*n* = 6). The AAN group of 100 mg/kg body weight was orally administered a single AAI dose in 0.5% carboxymethyl cellulose-Na. The control group was treated with 0.5% carboxymethyl cellulose-Na instead. On day 7 after administration, the rats from each group were placed in metabolic cages for the researchers to obtain 24 h urine samples. Blood samples were collected through the angular vein and centrifuged at 3000 × *g* for 10 min at 4 °C to obtain serum. Then, the rats were euthanized with CO~2~ gas, and their kidneys were immediately removed and snap-frozen in liquid nitrogen. All samples were stored at −80 °C until analysis. The animal experiments were in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International, and the animals were maintained in accordance with the "Guide for the Care and Use of Laboratory Animals". All the animal experiments were approved by the Animal Care Committee of Peking Union Medical College and Chinese Academy of Medical Sciences.

2.3. Biochemical analysis and histopathological staining {#sec2.3}
--------------------------------------------------------

Analyses of urine and serum were performed at the Deyi Diagnostics Corporation (Beijing, China). Concentrations of the urine protein (Upr) and creatinine, serum creatinine, blood urea nitrogen, serum high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured. Then, after 24 h, the urine-protein--creatinine ratio (Upr/Ucr) was calculated.

The kidneys were sectioned at a 10 μm thickness using a Leica CM1860 cryostat (Leica Microsystem Ltd., Wetzlar, Germany) at −20 °C and stained with hematoxylin and eosin (H&E) to reveal histopathological lesions.

2.4. Sample preparation and AFADESI-MSI analysis {#sec2.4}
------------------------------------------------

The kidneys were fixed atop a drop of saline on the cutting stage. Tissues were sectioned at a 10 μm thickness by using a Leica CM1860 cryostat (Leica Microsystem Ltd.) at −20 °C and thaw-mounted onto glass slides. All sections were stored at −80 °C until use and dried in a vacuum desiccator for approximately 30 min prior to analysis.

MSI experiments were performed on an AFADESI-MSI platform equipped with a Q-OT-qIT hybrid mass spectrometer (Orbitrap Fusion Lumos; Thermo Fisher Scientific, San Jose, CA, USA) and a home-made AFADESI ion source. The AFADESI-MSI analysis was carried out by continuously scanning the tissue surface in the *x*-direction at a constant rate of 200 μm/s, separated by a 200 μm vertical step in *y*-direction. The mass spectra were acquired in a positive full MS mode, with a scan range of 100--1000 Da, mass resolution of 120,000 at *m*/*z* 200, automatic gain control target of 2 × 10^5^, and maximum injection time of 70 ms. The spray voltage and transport tube voltage were set to 7 and 3 kV, respectively. Nitrogen (0.5 MPa) and acetonitrile/water (8:2, *v*/*v*, 5 μL/min) was used as the spray gas and spray solvent, respectively. The extracting gas flow was 45 L/min, and the capillary temperature was 350 °C. Data were acquired by using Xcalibur software (Version 2.2, Thermo Scientific).

2.5. Data processing and analysis {#sec2.5}
---------------------------------

Raw data files were converted to the cdf. format by using the Xcalibur software and then imported into custom-developed high-performance imaging software (MassImager 2.0, Beijing, China) for ion image reconstructions. After background subtraction and normalization, MS profiles from regions of interest (ROIs) were precisely extracted by matching H&E staining images of the adjacent section and generating separate two-dimensional data matrixes (*m*/*z*, intensity) in .txt format. The separated sample dataset matrixes were then imported into Markerview™ software 1.2.1 (AB SCIEX, Toronto, Ontario, Canada) for background deduction, peak picking, and peak alignment before multivariate statistical analyses. Multivariate analyses of the processed datasets from the ROIs were performed by using SIMCA-P 15.0 (Umetrics AB, Umea, Sweden). The metabolic profiles of the control and AAI-treated groups were compared by performing supervised multivariate OPLS-DA to achieve the maximum separation. Potential metabolic biomarkers were selected on the basis of their contribution to the class separation and variation within the data set. The paired *t*-test was used to compare the differences between the control group and the AAN group. Variables with *P* values \< 0.05 were considered to be indicative of statistical significance when compared those of the control group.

3. Results {#sec3}
==========

3.1. Optimization of conditions for AFADESI-MSI analysis {#sec3.1}
--------------------------------------------------------

The AFADESI ion source was successfully coupled with high mass resolution Q-OT-qIT hybrid mass spectrometer by a home-made interface (Supporting Information [Fig. S1](#appsec1){ref-type="sec"}). A stainless steel transport tube (i.d. 3 mm, o.d. 4 mm, length 500 mm) was used to connect the AFADESI system with the mass spectrometer and pump back the air flow. A sprayer-to-surface distance of 2.5 mm, a spray impact angle of 65°, and a collection angle of 15° were used to position the AFADESI spray. The parameters for the AFADESI-MSI platform were tuned to optimize the response of endogenous metabolites in kidney tissues. Most of the parameters for desorption/ionization of the AFADESI-MSI system were referred to in our previously reported work[@bib32]. The instrument was tuned to achieve a mass accuracy of \<2 ppm by external calibration, which gave a great advantage for rapid and direct identification of compounds in tissue.

Mass resolution is an important factor that influences the MS image quality of a tissue section. High mass resolution combined with a small bin width is of great advantage for discrimination of a large number of endogenous metabolites with similar exact mass values when complex biological samples are under investigation. The effect of mass resolution on the selectivity, sensitivity, and spatial resolution was investigated by analyzing adjacent tissue sections from the same rat kidney. As illustrated in [Fig. 1](#fig1){ref-type="fig"}, when the MS resolution was increased from 30,000 to 240,000, signals that differ in mass by only 0.02 Da could be effectively separated by mass spectrometry, resulting in a significant improvement in the selectivity of the MS image (with a bin width of Δ *m*/*z* = 0.005) and a significant increase in the number of ions detected in full-scan MS analyses (Supporting Information [Fig. S2A](#appsec1){ref-type="sec"}). However, the scanning speed decreased with increasing MS resolution in Orbitrap instruments, which might affect the sensitivity of the AFADESI-MS analysis differently from how it affected the selectivity of this analysis. When an MS resolution of 240,000 was employed, a significant decrease in total ion current was observed ([Fig. S2B](#appsec1){ref-type="sec"}). In addition, decreased spatial resolution was also observed, which was probably due to the decreased scanning speed at an MS resolution of 240,000. As a result, an MS resolution of 120,000 at *m*/*z* 200 was chosen for the AFADESI-MSI analysis of metabolites as a good balance among specificity, sensitivity, and spatial resolution. Other parameters, such as spray solvent, ion-spray needle voltage, vaporizer temperature, sheath gas, aux gas, sweep gas, and isolation window, were also optimized to achieve the maximum MS intensity.Figure 1MS spectra and images of metabolites with close *m*/*z* in rat kidney. (A) MS spectra of *m*/*z* 804.5309 and *m*/*z* 804.5524 ions in rat kidney. (B) MS image of *m*/*z* 804.5309. (C) MS image of *m*/*z* 804.5524. These two ions cannot be separated by mass spectrometry at MS resolutions of 30,000 and 60,000, but they can be distinguished at MS resolutions of 120,000 and 240,000. Scale bar: 2.5 mm.Figure 1

The reproducibility of the developed AFADESI-MSI method was assessed by analyzing adjacent renal slices on three successive days. Positive mode MS images for distribution of nine representative metbolites, including betaine (*m*/*z* 118.0864), glycerophosphocholine (*m*/*z* 280.0922), phosphatidylethanolamine (PE(36:4), *m*/*z* 778.4788), choline (*m*/*z* 104.1071), creatinine (*m*/*z* 136.0483), spermidine (*m*/*z* 146.1653), monoglyceride (MG(20:4), *m*/*z* 417.2405), linoleylcarnitine (*m*/*z* 424.3425), phosphatidylcholine (PC(38:4), *m*/*z* 832.5832), were extracted and compared, and the relative standard deviation (RSD) of the relative intensities of these metabolites in cortex, outer medulla, and inner medulla were also calculated to evaluate the intra-day precision. The reproducibility of MSI of betaine, glycerophosphocholine, and PE(36:4) are shown in [Fig. 2](#fig2){ref-type="fig"}, and the reproducibility of MSI of other six metabolites in Supporting Information [Fig. S3](#appsec1){ref-type="sec"}.Figure 2The reproducibility of the developed AFADESI-MSI method. Positive mode images for the distribution of betaine (*m*/*z* 118.0864), glycerophosphocholine (*m*/*z* 280.0922), and PE(36:4, *m*/*z* 778.4788) in adjacent renal slices analyzed on three successive days, and their relative standard deviation (RSD) of relative intensities in cortex, outer medulla, and inner medulla. Scale bar: 2.5 mm.Figure 2

MS images of these metabolites with different *m*/*z* values in adjacent tissue sections were comparative when using total ion current (TIC) normalization to correct the possible differences in instrumental drift with time, and most of the RSD of the relative intensities of these metabolites were less than 20%, indicating the AFADESI-MSI proposed here can reproducibly provide semi-quantitative data, which enables comparison between sections under different pharmacological treatments analyzed in different times.

3.2. Assessment of renal damage in AAI-treated rats {#sec3.2}
---------------------------------------------------

The body weight and biochemical parameters are summarized in [Table 1](#tbl1){ref-type="table"}. Body weight was significantly reduced in the AAI-treated rats relative to that in the control rats. Twenty-four hour Upr, Upr/Ucr, and Ucr were significantly increased in the AAI-treated rats, which indicated that AAI had caused the nephrotoxic effect in rats. However, blood creatinine and blood urea nitrogen were only slightly higher in the AAI-treated groups, probably due to their limitations relating to sensitivity and specificity in the detection of histological injury in preclinical toxicity studies[@bib36]^,^[@bib37]. In addition, serum triglycerides were significantly increased in the AAI-treated group. Serum cholesteryl esters, serum HDL, and serum LDL had no significant differences between the two groups.Table 1Body weight and biochemical parameters from aristolochic acid I (AAI)-treated and control rats on day 7 after administration.Table 1ParameterControlAAI-treated[a](#tbl1fna){ref-type="table-fn"}Body weight (g)284 ± 9.93233 ± 16.3\*\*Ucr (urine creatinine, mmol/L)4.17 ± 0.864.85 ± 1.32\*Upr (24 h urine protein, mg)55.7 ± 11.675.3 ± 23.7\*Upr/Ucr0.65 ± 0.221.03 ± 0.14\*Bcr (blood creatinine, μmol/L)26.0 ± 2.4527.6 ± 2.06Bun (blood urea nitrogen, mmol/L)5.00 ± 0.735.76 ± 0.45Serum CE (mmoL/L)1.48 ± 0.111.67 ± 0.29Serum TG (mmoL/L)0.66 ± 0.281.17 ± 0.45\*Serum HDL (mmoL/L)1.08 ± 0.051.17 ± 0.17Serum LDL (mmoL/L)0.28 ± 0.020.28 ± 0.08[^1]

Representative photomicrographs of H&E-stained kidney tissues are presented in [Fig. 3](#fig3){ref-type="fig"}. The histological examinations of kidneys indicated swelling and morphological changes in the AAI-treated rats. Extensive tubular necrosis and inflammatory cell infiltration occurred across the cortex and corticomedullary. These pathological changes indicated that AAI caused rapidly progressive tubulo-interstitial lesions in rats.Figure 3Photomicrographs of whole H&E stained renal sections from (A) control and (B) AAI-treated rats. The morphology of renal corticomedullary from control and AAI-treated rats are shown in images (C) and (D) with a 20-fold magnification, respectively.Figure 3

3.3. AFADESI-MSI analysis of AAI-treated rat kidneys {#sec3.3}
----------------------------------------------------

To investigate the biological effects induced by acute AAI exposure on the kidneys of rats, *in situ* molecular profiles of frozen sections of kidneys of the controls and dosed (100 mg/kg AAI) rats were acquired by AFADESI-MSI operated in the positive-ion mode with a mass range of *m*/*z* 100−1000. Representative AFADESI-MSI spectra from the renal cortex, outer medulla, and inter medulla are presented in Supporting Information [Fig. S4](#appsec1){ref-type="sec"}. Many peaks, corresponding to all types of metabolites, were observed in the AFADESI-MSI spectra; 512, 368, and 388 biological informative peaks (isotope excluded) were detected in the renal cortex, outer medulla, and inter medulla, respectively. The OPLS-DA scatter plot of the renal cortex, renal outer medulla, and renal inter medulla (Supporting Information [Fig. S5A](#appsec1){ref-type="sec"}) indicated that the three regions from the control groups could be clearly separated for the AFADESI-MSI analysis, which indicated obvious differences in metabolite profiling of these morphology regions. Compared with the control group, the trend of separation among the renal cortex, renal outer medulla, and renal inter medulla from the AAI-treated group were less significant ([Fig. S5B](#appsec1){ref-type="sec"}), probably because of tissue-specific effects of AAI exposure on metabolites in different morphology regions of the kidney.

A series of OPLS-DA analyses were performed to further investigate the metabolic effects of AAI exposure on the renal cortex, renal outer medulla, and renal inter medulla, respectively (Supporting Information [Fig. S6](#appsec1){ref-type="sec"}). An analysis of three latent variables indicated that the *R*^2^(*X*), *R*^2^(*Y*), and *Q*^2^(cum) values were 60.1%, 96.5%, and 54.8%, respectively, for the orthogonal projections to the latent structures\' discriminant analysis (OPLS-DA) model of the renal cortex; 76.4%, 88.2%, and 33.3%, respectively, for the OPLS-DA model of the renal outer medulla; and 71.8%, 84.7%, and 37.5%, respectively, for the OPLS-DA model of the renal inter medulla. The results indicated that the metabolomic alterations in the renal cortex after AAI treatment were more apparent than those in the renal outer medulla and renal inter medulla, which suggested that the renal cortex is more susceptible to AAI than the medulla. On the basis of a variable importance in projection threshold \>1.0 and *P* \< 0.05, we selected 85, 65, and 51 variables that accounted for the class separation as potential metabolic biomarkers for AA-induced toxicity of the renal cortex, renal outer medulla, and renal inter medulla, respectively. The structures of the potential biomarkers were provisionally identified on the basis of our previously described strategy. Briefly, tentative assignment of the structures of these potential biomarkers was first performed by searching the public databases METLIN (<http://metlin.scripps.edu/>), HMDB (<http://hmdb.ca/>), Massbank (<http://massbank.imm.ac.cn/MassBank>), and LIPID MAPS (<http://www.lipidmaps.org/>) in reference to the exact mass with a criterion of \<2 ppm for mass accuracy and isotope patterns, which generated a possible list of endogenous metabolites. Then, the high-resolution MS/MS experiments were conducted directly from renal sections to obtain structural information based on the interpretation of the metabolites' fragmentation patterns and database searches. As a result, a total of 38 discriminating metabolites were tentatively identified ([Table 2](#tbl2){ref-type="table"}). Fourteen metabolites, including creatinine, creatine, arginine, spermidine, choline, betaine, proline betaine, glycerophosphocholine, *N*-acetylhistamine, phosphoserine, inosine, fructosyl−lysine, carnitine, and linoleylcarnitine were provisionally identified on the basis of exact mass, exact MS/MS data, and databases. Because of the lack of useful fragmentation data, the remaining 27 discriminating metabolites were putatively assigned on the basis of exact mass and databases. The peak intensities of these 38 metabolites and their fold changes between the exposed and control groups are shown in Supporting Information [Table S1](#appsec1){ref-type="sec"}.Table 2Metabolites tentatively identified in the AFADESI-MSI positive-ion mode with renal distribution information in control and AAI-treated rats.Table 2Metabolite identificationElemental compositionAdductTheoretical (*m*/*z*)Measured (*m*/*z*)Delta[c](#tbl2fnc){ref-type="table-fn"} (ppm)Tissue distribution[d](#tbl2fnd){ref-type="table-fn"}ControlAAI-treatedCreatinine[a](#tbl2fna){ref-type="table-fn"}C~4~H~7~N~3~O\[M+Na\]^+^136.0481136.04831.47IM, CIM (↑), JC (↑)Creatine[a](#tbl2fna){ref-type="table-fn"}C~4~H~9~N~3~O~2~\[M+K\]^+^170.0326170.03281.18CC, M (↑)Arginine[a](#tbl2fna){ref-type="table-fn"}C~6~H~14~N~4~O~2~\[M+H\]^+^175.1190175.11910.57CIM (↑), JC (↑)Spermidine[a](#tbl2fna){ref-type="table-fn"}C~7~H~19~N~3~\[M+H\]^+^146.1652146.16530.68CJC (↑), M (↑)Choline[a](#tbl2fna){ref-type="table-fn"}C~5~H~13~NO\[M+H\]^+^104.1070104.10710.96CC (↑), M (↑)Betaine[a](#tbl2fna){ref-type="table-fn"}C~5~H~11~NO~2~\[M+H\]^+^118.0863118.08640.85OMOM (↓)Proline betaine[a](#tbl2fna){ref-type="table-fn"}C~7~H~13~NO~2~\[M+H\]^+^144.1019144.10211.39OMOM (↓)Glycerophosphocholine[a](#tbl2fna){ref-type="table-fn"}C~8~H~20~NO~6~P\[M+Na\]^+^280.0920280.09220.71IMIM (↑), JC (↑)*N*-Acetylhistamine[a](#tbl2fna){ref-type="table-fn"}C~7~H~11~N~3~O\[M+H\]^+^154.0975154.09771.30--JC (↑)Phosphoserine[a](#tbl2fna){ref-type="table-fn"}C~3~H~8~NO~6~P\[M+Na\]^+^207.9981207.9980−0.48C, OMJC (↑), M (↑)Inosine[a](#tbl2fna){ref-type="table-fn"}C~10~H~12~N~4~O~5~\[M+K\]^+^307.0439307.04410.65C, MC, M (↓)Fructosyl-lysine[a](#tbl2fna){ref-type="table-fn"}C~12~H~24~N~2~O~7~\[M+H\]^+^309.1656309.16590.97JCJC (↓)Carnitine[a](#tbl2fna){ref-type="table-fn"}C~7~H~15~NO~3~\[M+H\]^+^162.1125162.11260.62OMOM (↑)Linoleylcarnitine[a](#tbl2fna){ref-type="table-fn"}C~25~H~45~NO~4~\[M+H\]^+^424.3421424.34250.94OMOM (↓)MG(18:2)[b](#tbl2fnb){ref-type="table-fn"}C~21~H~38~O~4~\[M+K\]^+^393.2402393.24040.51CJC (↑)MG(20:4)[b](#tbl2fnb){ref-type="table-fn"}C~23~H~38~O~4~\[M+K\]^+^417.2402417.24050.72CJC (↑)MG(22:5)[b](#tbl2fnb){ref-type="table-fn"}C~25~H~40~O~4~\[M+K\]^+^443.2558443.25631.13--JC (↑)MG(22:6)[b](#tbl2fnb){ref-type="table-fn"}C~25~H~38~O~4~\[M+K\]^+^441.2402441.24060.91CJC (↑)DG(36:2)[b](#tbl2fnb){ref-type="table-fn"}C~39~H~72~O~5~\[M+K\]^+^659.5011659.50150.61C, JCC, JC (↑), OM (↑)DG(38:4)[b](#tbl2fnb){ref-type="table-fn"}C~41~H~72~O~5~\[M+K\]^+^683.5011683.50201.32C, JCC, JC (↑), OM (↑)DG(38:6)[b](#tbl2fnb){ref-type="table-fn"}C~41~H~68~O~5~\[M+K\]^+^679.4698679.47051.03C, JCJC (↑)DG(40:6)[b](#tbl2fnb){ref-type="table-fn"}C~43~H~72~O~5~\[M+K\]^+^707.5011707.50231.70CC, JC (↑)PC(34:3)[b](#tbl2fnb){ref-type="table-fn"}C~42~H~78~NO~8~P\[M+Na\]^+^778.5357778.53610.51C, MJC (↑)PC(36:4)[b](#tbl2fnb){ref-type="table-fn"}C~44~H~80~NO~8~P\[M+K\]^+^804.5514804.55170.37C, JC, OMJC (↑), OMPC(38:4)[b](#tbl2fnb){ref-type="table-fn"}C~46~H~84~NO~8~P\[M+Na\]^+^832.5827832.58320.60C, MC, JC (↑), MPC(40:4)[b](#tbl2fnb){ref-type="table-fn"}C~48~H~88~NO~8~P\[M+K\]^+^876.5879876.58820.34OMJC (↑), OMPC(40:5)[b](#tbl2fnb){ref-type="table-fn"}C~48~H~86~NO~8~P\[M+Na\]^+^858.5983858.5981−0.23OMJC (↑), OMPC(40:6)[b](#tbl2fnb){ref-type="table-fn"}C~48~H~84~NO~8~P\[M+K\]^+^872.5566872.55720.69C, OMC, JC (↑)PE(34:2)[b](#tbl2fnb){ref-type="table-fn"}C~39~H~74~NO~8~P\[M+K\]^+^754.4784754.47910.93C, JCC, JC (↓)PE(P-36:4)[b](#tbl2fnb){ref-type="table-fn"}C~41~H~74~NO~7~P\[M+Na\]^+^746.5095746.51010.80C, JC, OMC, JC (↓), OMPE(36:4)[b](#tbl2fnb){ref-type="table-fn"}C~41~H~74~NO~8~P\[M+K\]^+^778.4784778.47880.51C, JC,OMC, JC (↓), OM (↓)PE(P-38:5)[b](#tbl2fnb){ref-type="table-fn"}C~43~H~76~NO~7~P\[M+Na\]^+^788.4991788.49980.89C, JCC, JC (↓)PE(38:5)[b](#tbl2fnb){ref-type="table-fn"}C~43~H~76~NO~8~P\[M+K\]^+^804.4940804.49470.87C, OMC, OM (↓)PE(38:6)[b](#tbl2fnb){ref-type="table-fn"}C~43~H~74~NO~8~P\[M+K\]^+^802.4784802.47890.62C, OMC, OM (↓)PS(39:4)[b](#tbl2fnb){ref-type="table-fn"}C~45~H~80~NO~10~P\[M+H\]^+^826.5593826.56061.57C, JCC, JC (↓)PS(35:1)[b](#tbl2fnb){ref-type="table-fn"}C~41~H~78~NO~10~P\[M+Na\]^+^798.5256798.5252−0.50C, JCC, JC (↓)PG(36:0)[b](#tbl2fnb){ref-type="table-fn"}C~42~H~83~O~10~P\[M+Na\]^+^801.5616801.5615−0.12C, JCC, JC (↑)PG(42:8)[b](#tbl2fnb){ref-type="table-fn"}C~48~H~79~O~10~P\[M+Na\]^+^869.5303869.5292−1.26CC, JC (↑)[^2][^3][^4][^5]

To further evaluate the association of these metabolites with AAI-induced nephrotoxicity, the MS images of these metabolites was extracted and compared with the histological features of AAI-treated kidney obtained by H&E staining of adjacent sections. The results indicated that the distribution of these metabolites showed a good spatial match with histopathological renal lesions ([Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}).Figure 4Spatial distribution and changes of metabolites involved in arginine--creatinine metabolic pathway in the kidneys from AAI-treated group and control group. The red fonts represent upregulated metabolites. Scale bar: 2.5 mm.Figure 4Figure 5Spatial distribution and changes of metabolites related to choline metabolism in the kidneys from AAI-treated group and control group. The red fonts represent upregulated metabolites. Scale bar: 2.5 mm.Figure 5Figure 6Spatial distribution and changes of metabolites related to lipids metabolism in the kidneys from AAI-treated group and control group. The red fonts represent upregulated metabolites and blue fonts represent downregulated metabolites. Scale bar: 2.5 mm.Figure 6Figure 7Spatial distribution and changes of *N*-acetylhistamine, phosphoserine, inosine, and fructosyl-lysine in the kidneys from AAI-treated group and control group. The red fonts represent upregulated metabolites and blue fonts represent downregulated metabolites. Scale bar: 2.5 mm.Figure 7

4. Discussion {#sec4}
=============

4.1. Perturbation on arginine--creatine metabolic pathway and urea cycle {#sec4.1}
------------------------------------------------------------------------

The spatial distribution and changes in arginine, creatine, and creatinine ([Fig. 4](#fig4){ref-type="fig"}) demonstrated that the concentration of arginine, creatine, and creatinine were significantly increased, especially in the juxtamedullary cortex and inner medulla of kidneys, in the AAI-treated rats, respectively. Arginine is an important amino acid involved in multiple physiological processes, such as cell division, wound healing, ammonia removal from the body, immune function, blood pressure regulation, and hormones release[@bib38]. Creatine and creatinine are downstream metabolites of the arginine--creatinine metabolic pathway. The present study suggested that AAI led to upregulation of the arginine--creatine metabolic pathway, which has been reported in patients with chronic kidney disease[@bib39]^,^[@bib40].

The concentration of spermidine was significantly increased in the juxtamedullary cortex and medulla of kidneys in the AAI-treated rats ([Fig. 4](#fig4){ref-type="fig"}). Spermidine synchronizes an array of biological processes, such as Ca^2+^, Na^+^, K^+^-adenosine triphosphate (ATP)ase, thus maintaining membrane potential and controlling intracellular pH and volume. Spermidine is a precursor of spermine and a downstream metabolite of the urea cycle, which is part of the arginine biosynthesis metabolic pathway[@bib39]. The increased spermidine and arginine suggested that AAI led to dysfunction of the urea cycle metabolic pathway, which was consistent with the finding of a previous study in which alteration of other metabolites related to the urea cycle, including aspartic acid, citrulline, and spermine, was associated with AAI toxicity[@bib22].

4.2. Disturbance of choline metabolism {#sec4.2}
--------------------------------------

The spatial distribution of choline and its metabolites in rat kidney is illustrated in [Fig. 5](#fig5){ref-type="fig"}. As a component of cell membranes, mitochondrial membranes, and the neurotransmitter acetylcholine, choline is involved in various biological pathways[@bib41]. Betaine and glycerophosphocholine are metabolites of the oxidation and phosphorylation of choline, respectively. Known as important osmoprotectants, glycerophosphocholine and betaine participate in the formation of the axial osmolality gradient and are able to protect renal medulla cells against damaging influence induced by a high-urea environment[@bib41]. Furthermore, they contribute to the maintenance of the structure and function of biological macromolecules in cells. Choline and glycerophosphocholine have been found to be increased significantly in the renal cortex and medulla of AAI-treated rats, whereas betaine and prolinebetaine have been found to be decreased significantly in the renal outer medulla; this indicates alterations of organic ion transportation in AAI-treated rats[@bib42].

4.3. Disturbance of lipids' metabolism {#sec4.3}
--------------------------------------

The concentrations of carnitine and palmitoylcarnitine were significantly increased in the renal medulla, especially in the juxtamedullary cortex of the kidneys of the AAI-treated rats ([Fig. 6](#fig6){ref-type="fig"}). Carnitine and acylcarnitine have an important role in cellular energy distribution by mediating the transportation and metabolism of fatty acids. The binding of fatty acids to carnitine results in formation of acylcarnitine, which is essential for transportation of fatty acids to the mitochondria for energy production. The kidney is rich in mitochondria and has high energy demands. Therefore, mitochondrial dysfunction of the kidney has a critical role in the pathogenesis of kidney diseases[@bib43]. The accumulation of carnitine and the reduction of linoleylcarnitine suggest that AAI leads to fatty acid metabolism disorder and mitochondrial kidney dysfunction. In addition, because these binding reactions have been found to be catalyzed by carnitine palmitoyltransferase 1 (CPT1)[@bib42], the accumulation of carnitine and the reduction of linoleylcarnitine suggested that AAI might lead to fatty acids metabolic disorder by inhibiting the activity of CPT1.

The spatial distribution and changes in lipids are illustrated in [Fig. 6](#fig6){ref-type="fig"}. A variety of lipids, including monoglyceride (MG), diglyceride (DG), triglyceride (TG), phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidylethanolamine (PE), were changed significantly in the AAI-treated rats. MG(18:2), MG(20:4), MG(22:5), MG(22:6), DG(36:2), DG(38:4), DG(38:6), DG(40:6), PC(34:3), PC(36:4), PC(38:4), PC(40:4), PC(40:5), PC(40:6), PG(36:0), and PG(42:8) were upregulated in the renal juxtamedullary cortex; PE(34:2), PE(P-36:4), PE(36:4), and PE(38:6) were downregulated in the renal juxtamedullary cortex and medulla; PE(P-38:5) was downregulated in the renal juxtamedullary cortex; and PE(38:5) was downregulated in the renal medulla. These results indicated disturbance of fatty acid metabolism. Lipids have many important biological functions and are involved in regulating a variety of life activities, including energy conversion, material transportation, information recognition and transmission, cellular development, differentiation, and apoptosis[@bib44]^,^[@bib45]. These findings indicated the potential role of lipid mediators in development of AAN, as reported in previous studies[@bib20]^,^[@bib21].

4.4. Effects on metabolism of N-acetylhistamine, phosphoserine, inosine, and fructosyl--lysine {#sec4.4}
----------------------------------------------------------------------------------------------

The spatial distribution and changes in *N*-acetylhistamine, phosphoserine, inosine, and fructosyl*--*lysine are illustrated in [Fig. 7](#fig7){ref-type="fig"}. *N*-Acetylhistamine was upregulated in the renal juxtamedullary cortex. *N*-Acetylhistamine is a metabolite of histamine and an important factor in anaphylactoid reactions[@bib46]. The results suggested that AAI caused anaphylactoid reactions in the renal juxtamedullary cortex, and *N*-acetylhistamine may have an important role in the progression of AAI-induced renal injury.

Phosphoserine was increased significantly in the renal juxtamedullary cortex. Phosphoserine is an ester of serine and phosphoric acid, and an important intermediate product of the serine synthesis pathway. The increased phosphoserine probably reflected increased serine synthesis and/or altered filtration by kidneys.

Treatment with AAI caused a significant decrease in inosine in the renal outer medulla. Inosine is typically formed as a breakdown product of ATP and is a known marker of oxidative stress. The kidney is rich in mitochondria and highly demanding of energy. Therefore, mitochondrial dysfunction has a vital role in the pathogenesis of renal diseases[@bib47]. The decrease may reflect interruption of energy metabolism and mitochondrial dysfunction of the kidney.

Fructosyl--lysine, a conjugate of fructose and lysine, was downregulated in the destroyed area. Lysine is a cationic amino acid and the substrate of organic cationic transporters. The decrease in fructosyl--lysine may reflect the altered activity of renal transporters in the AAI-treated rats[@bib42].

The underlying mechanism responsible for the observed changes in different metabolites in the renal tissues of AAI treated rats is presently unclear. But, changes in the content and distribution of most metabolites appear to be associated with mitochondrial dysfunction. One possible explanation for these results is that AAI exposure may induce mitochondrial damage in renal tubular epithelial cell[@bib43]^,^[@bib47]^,^[@bib48], resulting the dysfunction of the mitochondrial lipid metabolism, interruption of energy metabolism, altered activity of ATP-dependent renal transporters, apoptosis, and inflammation. In addition, most of discriminating metabolites in the lesion area were found to be lipids, indicating the lipid metabolism pathway may be closely associated with the nephrotoxicity of aristolochic acids and lipid metabolites may have a potential to be tissue-specific nephrotoxic biomarkers.

5. Conclusions {#sec5}
==============

In summary, an *in situ* metabolomics method based on AFADESI-MSI was developed to investigate the spatially resolved metabolic effects induced by AAI exposure. The results indicated that the distribution of 38 metabolites related to the arginine--creatine metabolic pathway, the urea cycle, and metabolism of lipids, histamine, serine, lysine, and ATP were changed significantly in the AAI-treated rats. These findings indicated that the proposed AFADESI-MSI-based metabolomics strategy was capable of visualizing unique distributions and alterations of both known and unknown endogenous metabolites with high throughput and high molecular specificity, without the need for labeling and complicated sample pretreatment process. Nevertheless, the molecular images obtained by AFADESI-MSI analysis can be correlated directly with histological staining images, which is helpful for discovery of *in situ* biomarkers closely related to drug toxicity and for revealing the potential molecular mechanism underlying the toxicity.
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[^1]: *P* values were calculated by performing the independent Student\'s t-test. \**P* \< 0.05; \*\**P* \< 0.01; AAI, aristolochic acid I. CE, cholesteryl ester ; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride.

[^2]: Metabolites provisionally identified on the basis of exact mass, exact MS/MS data, and databases.

[^3]: Metabolites putatively assigned on the basis of exact mass and databases with no useful fragmentation data.

[^4]: Delta=(Measured *m*/*z*−Theoretical *m*/*z*)/Theoretical *m*/*z* × 10^6^.

[^5]: C, cortex; JC, juxtamedullary cortex; M, medulla; OM, outer medulla; IM, inner medulla. (↑) Indicates significant increase in local abundance; (↓) denotes significant decrease in local abundance. The peak intensities of these 38 metabolites and their fold changes between the exposed and control groups are shown in Supporting Information [Table S1](#appsec1){ref-type="sec"}. --Not applicable.
